Health Related Quality of Life in Patients With Hodgkin’s Lymphoma Receiving Brentuximab Vedotin in University Hospital Establishment of Oran (Uheo) - Algeria.

For patients with Hodgkin’s lymphoma (HL) treated with Brentuximab vedotin (BV), quality of life (QoL) depends primarily on the effectiveness of treatment, side effects management, the psychological impact of diagnosis and treatment, and how the constraints associated with drug delivery affect their daily lives. The main objective is to evaluate Qol using the Europeen Organization For Research and Treatment of Cancer questionnaire in HL patients under BV at the UHEO to improve overall patient management and optimize therapeutic outcomes throughout their treatment path care. Materials and methods. The study included patients from different regions of Algeria who had been treated at the UHEO’s hematology department with HL under BV since January 2024. Questionnaires assessing various aspects such as potentially quality of life, were completed by the patients themselves. Results. In total 28 patients were included, 57.15% were women. The average age of the population was 33+/-17 years with extremes of 15 and 72. A statistically significant difference was found between the items of the QLQ-HL27 as well as for the items of the QLQ-C30 according to age, gender, region and stage of disease (p<0.05). No influence of age was found on diarrhea (p=0.10), nor any statistical difference between pain (p=0.78) and financial impact (p=0.63) compared to gender. Conclusion. A statistical difference of the majority of items in QLQ-C30 and QLQ-HL27 compared to age, gender, region and stage of disease in LH patients treated with BV.